Semaglutide vs Tirzepatide: Comparing GLP-1 Weight Loss Options
Two medications, one treatment category
Semaglutide and tirzepatide are both once-weekly injectable GLP-1 receptor agonist medications indicated for chronic weight management, sharing a common therapeutic category but differing in receptor targets, dosing ranges, and clinical-trial weight loss outcomes.
Semaglutide and tirzepatide are both GLP-1 receptor agonist medications used for weight loss. They share the same general category but differ in how they work, how they are dosed, and the clinical outcomes observed in studies. This guide breaks down the key differences so you can understand what your provider is evaluating when they make a treatment recommendation. For a complete FAQ covering both medications — including cost, dosing schedules, and what to expect — see our GLP-1 resource hub.
How they work: single vs dual action
Semaglutide is a single-receptor agonist targeting GLP-1 receptors only, while tirzepatide is a dual-receptor agonist targeting both GLP-1 and GIP receptors — the addition of GIP activation is the key pharmacological distinction between the two medications.
Semaglutide is a single-receptor agonist — it activates GLP-1 receptors only. Tirzepatide is a dual-receptor agonist — it activates both GLP-1 and GIP receptors. GIP is another incretin hormone that plays a role in metabolism and insulin regulation. The addition of GIP activation is what distinguishes tirzepatide and is thought to contribute to its potentially greater effect on weight loss in some studies.
Typical results observed in studies
In pivotal clinical trials, semaglutide 2.4mg produced mean weight loss of approximately 15% of baseline body weight over 68 weeks (STEP 1), while tirzepatide 15mg produced mean weight loss of approximately 20-22% over 72 weeks (SURMOUNT-1) — both values substantially exceeding the placebo-adjusted loss observed in each trial.
Head-to-Head Trial Comparison (separate studies; no direct head-to-head RCT)
| Metric | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Trial program | STEP 1 | SURMOUNT-1 |
| Dose | 2.4 mg once-weekly | 15 mg once-weekly |
| Duration | 68 weeks | 72 weeks |
| Mean weight loss (% body weight) | ~15% | ~20-22% |
| Mean weight loss (absolute) | ~15.3 kg (33.7 lbs) | ~20.9 kg (46.0 lbs) |
| Placebo-adjusted loss | ~12.4% | ~17.8% |
| Participants achieving at least 20% loss | ~32% | ~57% |
These trials were conducted independently — no direct head-to-head randomized comparison exists. | Results are from brand-name formulations at maximum studied doses. Individual and compounded results vary.
It is important to understand that these studies used brand-name medications at specific doses. Compounded versions — which are what Surfbound providers may prescribe — are prepared by licensed compounding pharmacies and are not FDA-approved. Results with compounded medications have not been studied in the same way.
Dosing and administration
- Administration route
- Both: once-weekly subcutaneous injection
- Semaglutide dose range
- 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance)
- Tirzepatide dose range
- 2.5 mg → 5.0 mg → 7.5 mg → 10.0 mg → 12.5 mg → 15.0 mg (maintenance)
- Titration
- Both follow a gradual 4-week-per-step escalation protocol to minimize gastrointestinal side effects
- Determination
- Starting dose and titration schedule are individualized by a licensed provider based on health profile
Side effect profiles
- Most common
- Gastrointestinal: nausea, vomiting, diarrhea, constipation. Most pronounced during dose escalation; typically improve with time.
- Nausea incidence (trials)
- Semaglutide: ~44%; Tirzepatide: ~33%. Rates decrease significantly after week 20.
- Boxed warning
- Both carry FDA boxed warning for thyroid C-cell tumors (rodent studies; human relevance unknown). Not studied in humans for carcinogenicity.
- Contraindicated for
- Personal or family history of medullary thyroid carcinoma; Multiple Endocrine Neoplasia syndrome type 2.
Which one should you choose?
The choice between semaglutide and tirzepatide is a medical decision made by a licensed provider after reviewing your health history, BMI, current medications, allergies, treatment goals, and clinical factors — the provider may recommend one medication over the other or determine that neither is appropriate.
You do not need to choose. Surfbound providers determine which medication — if any — is medically appropriate based on a review of your health history, BMI, current medications, allergies, treatment goals, and other clinical factors. The provider may recommend one over the other, or may determine that neither is appropriate for you.
Access and availability also play a role. Compounded medications may be prescribed for an individual patient when clinically appropriate and permitted under applicable federal and state law. Your provider considers all of these factors when making a recommendation.
Ready to take the next step?
Complete your intake for provider reviewFrequently asked questions
Not for everyone. While clinical trials showed higher average weight loss with tirzepatide, individual response varies significantly. Some people respond better to one medication than the other. A provider evaluates your specific health profile to determine which option may be most appropriate.
Switching between GLP-1 medications is a medical decision that should only be made under provider supervision. Your provider can assess whether a switch is appropriate based on your response to treatment, side effects, and treatment goals.
Pricing varies based on the pharmacy, dosage, and whether the medication is brand-name or compounded. Brand-name tirzepatide may have a higher list price. Compounded pricing depends on the specific formulation and pharmacy. Surfbound shows pricing before checkout.
Yes. Both medications are contraindicated for people with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or known hypersensitivity to any component. Other medical conditions may also make treatment inappropriate. A provider review is required to determine eligibility.
Want more evidence-based health research from Surfbound?
Add Surfbound as a Preferred Source on Google